Subconjunctival bevacizumab for corneal neovascularization

被引：65

作者：

Doctor, Priyanka P. ^{[1
]}

Bhat, Pooja V. ^{[1
]}

Foster, C. Stephen ^{[1
]}

机构：

[1] Harvard Univ, Sch Med, Massachusetts Eye Res & Surg Inst, Ocular Immunol & Uveitis Fdn, Cambridge, MA 02142 USA

来源：

CORNEA | 2008年 / 27卷 / 09期

关键词：

subconjunctival bevacizumab; avastin; corneal neovascularization;

D O I：

10.1097/ICO.0b013e31817786ad

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Purpose: To describe whether subconjunctival bevacizumab decreases corneal in patients with ocular surface inflammatory diseases. Methods: The study is a retrospective case series that includes 8 eyes of 7 patients with corneal neovascularization. Patients received 1-3 injections of 2.5 mg subconjunctival bevacizumab. changes, were assessed clinically by the same investigator at each visit. Results: Subconjunctival bevacizumab was well-tolerated without obvious, corneal side effects. All 8 eyes of the 7 patients showed a recduction in the neovascularized area. Conclusions: Subconjunctival bevacizumab may provide an additional strategy in improving vision or improving success of corneal grafts in these patients.

引用

页码：992 / 995

页数：4

共 24 条

[11]

Edelman JL, 1999, INVEST OPHTH VIS SCI, V40, P1112

[12] CORNEAL NEOVASCULARIZATION - PATHOGENESIS AND INHIBITION [J].